ZTS · Q1 2026 Earnings

Bearish

Zoetis

Reported May 7, 2026

30-second summary

30-second take: Zoetis posted Q1 revenue of $2.262B (+3% reported, flat organic operational) and adjusted EPS of $1.53, then lowered FY2026 guidance across every meaningful line — organic operational revenue growth floor cut to 2% from 3%, adjusted EPS midpoint down $0.125 to $6.925, reported EPS midpoint down $0.275 to $6.425. U.S. Companion Animal came in at -11% YoY, and management explicitly conceded ex a ~$100M Q4-to-Q1 fiscal-alignment shift, global organic growth would have been -5% in the quarter. The defensive narrative has now hardened into an actual cut, with the "decisive action to sharpen commercial execution" language replacing the prior "position of strength" framing — this is no longer a credibility test, it's a thesis break.

Headline numbers

EPS

Q1 FY2026

$1.53

-5.6% vs est.

Revenue

Q1 FY2026

$2.26B

+3.0% YoY

-1.7% vs est.

Gross margin

Q1 FY2026

71.7%

Operating margin

Q1 FY2026

33.5%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$2.26B	+3.0%	$2.39B	-5.2%
EPS	$1.53	—	$1.48	+3.4%
Gross margin	71.7%	—	70.3%	+140bps
Operating margin	33.5%	—	31.9%	+160bps

Guidance

Management lowered full-year FY2026 guidance across revenue, EPS, and net income, driven by Q1 underperformance in U.S. Companion Animal (-11% YoY) despite strength in International and Livestock segments.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
EPS (Non-GAAP)	Q1 FY2026	—	$1.53	-5.6% vs consensus estimate of $1.62	Missed
Revenue	Q1 FY2026	—	$2.262 billion	-1.7% vs consensus estimate of $2.300B	Missed

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY 2026	$9.825 billion to $10.025 billion	$9.680 billion to $9.960 billion	-$0.145B low end, -$0.065B high end (mid-point down $0.105B or -1.1%)	Lowered
Adjusted Diluted EPS	FY 2026	$7.00 to $7.10	$6.85 to $7.00	-$0.15 low end, -$0.10 high end (mid-point down $0.125 or -1.8%)	Lowered
Reported Diluted EPS	FY 2026	$6.65 to $6.75	$6.35 to $6.50	-$0.30 low end, -$0.25 high end (mid-point down $0.275 or -4.1%)	Lowered
Revenue Organic Operational Growth	FY 2026	3% to 5%	2% to 5%	-1 percentage point at low end	Lowered
Adjusted Net Income	FY 2026	$2.975 billion to $3.025 billion	$2.870 billion to $2.950 billion	-$0.105B low end, -$0.075B high end (mid-point down $0.090B or -3.0%)	Lowered
Adjusted Net Income Organic Operational Growth	FY 2026	3% to 6%	2% to 6%	-1 percentage point at low end	Lowered

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
U.S. Companion Animal	$0.865B	-11.0%
U.S. Livestock	$0.225B	+7.0%
International Companion Animal	$0.654B	+7.0%
International Livestock	$0.495B	+14.0%
Dogs and Cats	$1.443B	-5.0%
Cattle	$0.392B	+11.0%
Swine	$0.123B	+11.0%
Poultry	$0.118B	+8.0%
Companion Animal Organic Operational Growth	-4%	—
Livestock Organic Operational Growth	12%	—

Other KPIs

Q1 FY2026

Segment	Q1 FY2026
U.S. Segment Gross Margin	82.2%
International Segment Gross Margin	70.9%
U.S. Organic Operational Revenue Growth	-8%
International Organic Operational Revenue Growth	10%
Pipeline Blockbuster Candidates	12+
FY2026 Organic Operational Revenue Growth Guidance	2% to 5%

Management tone

This quarter management is reaching for new defensive vocabulary: "We are taking decisive action to sharpen commercial execution and drive cost discipline." "Decisive action" is the language of a course correction, not a strategy in place — it is the verbal admission that the prior plan did not work.

The competitive dynamic narrative has undergone a structural inversion. Kristin explicitly retired the prior thesis that new entrants expand the category: "In contrast to what we've seen historically, these new entrants have not yet translated into overall market expansion... Unlike prior competitive cycles, we do not currently have the benefit of underlying market expansion to cushion the revenue effect of competitive share shifts." This is management conceding the historical playbook does not apply to the current cycle. The implication for the bull case is severe — pricing power, category expansion, and share durability were the three pillars of the Zoetis algorithm, and management has now named one of them as structurally compromised.

The U.S. companion animal diagnosis has moved from cyclical to structural. With U.S. Companion Animal at -11%, management disclosed that ex the ~$100M fiscal-alignment shift the global business would have shrunk 5%. The CFO's framing was unusually candid: "This quarter, our promotions underperformed expectations and in-market demand softened." Promotions underperforming is an execution miss; in-market demand softening is a structural read. Both are now being named together, and the combination is what produced the cut.

The pipeline timing is the bridge management is asking investors to underwrite. Kristin said the blockbuster pipeline begins "delivering significant value for the end of 27 and into 28" — a near-explicit acknowledgment that the next 6–8 quarters require execution to bridge to the next innovation cycle, with no new launches to lean on. The hedging language has stacked: "we see a path for the market to return to growth over time," "meaningful market expansion opportunities remain," "we believe." These are the verbal markers of a management team that has lost the option to point to a near-term catalyst.

Recurring themes management leaned on this quarter:

U.S. companion animal structural market contraction and clinic visit pressurePet owner price sensitivity constraining premium product demand despite historical pricing powerCompetitive fragmentation without category expansion limiting growth offsetsInternational emerging markets providing runway vs. developed market headwindsInnovation pipeline timing pushed to late 2027/2028; bridging period requires execution focusCost discipline and commercial sharpening to offset near-term revenue headwinds

Risks management surfaced:

U.S. companion animal market contraction and sustained clinic traffic declineIntensified generic competition in established products (Convenia, Sirenia) with meaningful share lossCompetitor pricing and promotional intensity without corresponding market expansionPet owner macro-driven price sensitivity reducing demand for premium preventive and chronic care productsInnovation pipeline blockbuster launches delayed until late 2027/2028, leaving near-term growth dependent on execution rather than new launches

Q&A highlights

Michael Riskin · Bank of America

Given increasing competitive pressure, macro consumer challenges persisting 1-2+ years, and major product launches still 2 years out, what can Zoetis do in the near term to turn around performance? Also, how does 1Q26 organic decline of ~0% (or down 4-5% on old calendar basis) bridge to low-to-mid single digit full-year growth guidance?

Management highlighted positive trends in PARA share gains, Labrella stabilization, and excitement about long-acting formulations launching end-of-year. On near-term strategy: sharpening execution, leveraging broad portfolio, using DTC for market expansion, and focusing on affordability through loyalty programs and point-of-sale options. For guidance bridge: initial guidance already contemplated first-half/second-half dynamics; stabilization occurring in key franchises; easier 2H comps; and actions being taken support the range, though it was widened to reflect market uncertainty.

PARA share gains from end of prior year into Q1 2026Labrella stabilized, expected to return to growthLong-acting site appoints launching end of yearInitial guidance contemplated first-half to second-half dynamics

Erin Wright · Morgan Stanley

What quarterly progression is implied for companion animal? Is distributor/retail restock baked in? How much headwind from destocking? Detail on script denials at retail. Clarify 2026 stocking/destocking comps. On 200bp accounting benefit: will this recur in 2027, and when can Zoetis return to typical 6-8% operational revenue growth?

Management explicitly stated no assumption of inventory rebound; operating at low end of new (post-2023) normalized range and not assuming return to pre-2023 levels. Script denials are a headwind; retail growth slowed to ~10% from prior 25-30% range. Key franchises expected to grow low-to-mid single digits (step down from initial guidance). On 2027: the 200-250bp accounting benefit will lap and be a headwind in 2027; no forward guidance provided, but management executing to drive top-line and bottom-line performance with P&L leverage.

Distributor inventory operating at low end of new normalized range; no rebound assumedInventory levels well below pre-2023 levelsRetail growth rate in low double digits (~10%), down from 25-30% prior yearsScript denials creating retail headwind

Brandon Vasquez · William Blair

Isn't Zoetis entering a 'new world' in companion animal—one less durable and attractive, with prices not sticking, markets not expanding, generics arriving, and brand less powerful? What gives management hope this reverses back to the 'old' animal health market?

Management pushed back on the 'new world' thesis: structural demand for veterinary care remains very strong due to human-animal bond and large untreated populations. Urgent care and diagnostics remain strong, suggesting pet owners still seek care despite affordability challenges. Price increases will stabilize. No generics expected in key categories (DERM, pain, PARA) for many years; current competition is non-generic. Sequential trends improving in OA pain and PARA. Differentiation, innovation, brand strength, and veterinarian service will endure.

Clinic revenue grew 3% driven entirely by price; clinic visits down 3%Urgent care and diagnostics remain strongNo generics expected in DERM, pain, or PARA in near termSequential trends improving in OA pain and PARA

Chris Scott · JP Morgan

What are Zoetis' latest pricing assumptions for 2026, given competitive promotion activity? Is company reacting with price cuts or accepting share loss? Should U.S. companion animal be expected to be down for the full year, or flat/growing?

Management is not competing on price; focus remains on differentiated portfolio, breadth, service, and execution. Pricing expectations revised down to 1-2% from prior 2-3%. Company took price in Q1 and expects to continue at lower levels given current challenges. Selective price actions in generic-competition areas; leveraging promotions but prioritizing innovation and differentiation. On U.S. companion: no species-level guidance provided, but global diversification noted; international companion grew 7%; key franchises expected to grow low-to-mid single digits; livestock expected mid-to-high single digits.

Pricing expectations revised to 1-2% for 2026 (from 2-3%)Not planning to compete through price; premium innovative brand positioning maintainedSelective price actions in areas with generic competitionInternational companion animal group grew 7% in Q1

John Block · Stifel

Can you call out the specific channel/inventory impact in Q1 for U.S. pet health? Is Zoetis changing competitive response strategy on atopic derm or Trio franchises—unilateral price changes, targeted promotions, or bundling/service focus? Is the company pivoting to deliver cheaper alternatives?

Management stated channel normalization is difficult to separate from macro/soft demand; distributors ordered less than they shipped out due to in-market softness and underexecution of expected promotions. No species-level channel breakdown provided. On competitive response: company is not lowering list prices; continues seasonal and cross-portfolio promotions (standard approach). Real focus is on affordability at point-of-sale for pet owners, not at veterinarian level—enhancing point-of-sale loyalty programs to address economic pressure vs. simply scanning receipts for delayed cashback. Programs being altered for immediate point-of-sale relief.

Distributors ordered less than shipped out in Q1 due to macro softness and promotion underexecutionList prices not being loweredSeasonal and cross-portfolio promotions continuing as standardFocus on point-of-sale affordability programs for pet

Answers to last quarter's watch list

Q1 FY2026 organic operational revenue growth print vs the FY 3–5% range — Q1 organic operational growth came in at flat (0%), and ex the ~$100M Q4 FY2025-to-Q1 FY2026 fiscal alignment shift, global organic operational would have been -5%. This is well below the 3% floor of the original guide and triggered the cut to 2–5%. The FY midpoint now requires H2 inflection of ~3% organic operational against deteriorating trends. Status: Resolved negatively

U.S. Companion Animal inflection — U.S. Companion Animal came in at -11% YoY reported and -11% organic operational in Q1 FY2026. The deterioration thesis is fully confirmed. Status: Resolved negatively

Trio U.S. growth rate — U.S. Simparica Trio posted $222M, declining 8%. Commentary referenced "sequential trends improving" with PARA share gains from late FY2025 into Q1 FY2026, but the franchise remains in decline. Status: Resolved negatively

Adjusted gross margin trajectory — Q1 FY2026 adjusted gross margin came in at 71.8%, down ~10bps reported but +140bps ex-FX vs prior-year Q1, supported by price and lower manufacturing costs partially offset by mix. This is the only positive resolution from the prior list. Status: Resolved positively

Librela U.S. patient starts disclosure — No hard U.S. patient starts number disclosed. Management said U.S. Librela revenue increased sequentially for the first time in six quarters and stabilization is occurring through medical education and specialist engagement. The qualitative read is incrementally constructive but still lacks the disclosure that would confirm defendability. Status: Continue monitoring

Pricing realization vs the 2–3% FY2026 assumption — Management explicitly revised pricing expectations to 1–2% for FY2026, down from 2–3%, in the Chris Scott Q&A. The downside scenario flagged a quarter ago — vets continuing to resist price increases — has played out, and the 100bps reduction in price contribution is a meaningful driver of the guidance cut. Status: Resolved negatively

What to watch into next quarter

Q2 FY2026 U.S. Companion Animal print — watch whether the -11% Q1 reading bottoms, stabilizes, or extends. A second consecutive double-digit decline would invalidate the 2–5% FY range and force a second cut. Management's bridge to FY midpoint requires inflection starting in Q2.

H2 FY2026 organic operational growth implied by Q2 print — at flat Q1 organic operational, H2 needs to average ~3–4% organic operational growth to hit the FY midpoint. Any Q2 read below 2% organic operational makes the FY range mechanically unreachable.

Adjusted vs reported EPS divergence — the $0.15 gap between adjusted EPS midpoint cut ($0.125) and reported EPS midpoint cut ($0.275) implies ~$60–70M of additional non-GAAP charges baked into the guide. Watch whether Q2 quantifies the restructuring/cost-discipline charges and whether they expand beyond the current guide.

Pricing realization vs the new 1–2% assumption — if Q2 commentary points to price contribution running below 1%, the lower end of the new 2–5% organic range is at risk. The pricing floor has now been reset twice in two quarters.

Distributor inventory and the 200–250bps fiscal alignment tailwind — the accounting benefit becomes a headwind in FY2027. Watch for any Q2 disclosure that frames an underlying organic algorithm ex the alignment benefit — that's the cleanest read on what FY2027 starts from.

Librela U.S. patient starts ahead of Lenivia/Portela launches — management said U.S. Librela revenue grew sequentially for the first time in six quarters but offered no patient-starts number. A hard figure in Q2 is the cleanest read on whether the OA pain franchise can be defended through the cannibalization transition.

Sources

Zoetis Q1 FY2026 earnings press release (SEC EDGAR filing, exhibit99q12026.htm)
Zoetis Q1 FY2026 earnings call prepared remarks and Q&A

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.